Clinical Trial Update: Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 trial evaluating the combination of bicalutamide and raloxifene in metastatic or hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Raloxifene (raloxifene)
• bicalutamide (bicalutamide)

Snippet

Sponsor: Mayo Clinic | Conditions: Prostate Cancer, Adenocarcinoma of the Prostate | EARLY_Phase 1 | Status: COMPLETED